Alofanib|1612888-66-0|(RPT835)-陌孚医药/Medlife

您当前的位置：

Alofanib (Synonyms: RPT835)

目录号: PL04752 纯度: ≥98%

CAS No. :1612888-66-0

商品编号	规格	价格	会员价
PL04752-5mg	5mg	¥1112.73	请登录
PL04752-10mg	10mg	¥1607.27	请登录
PL04752-25mg	25mg	¥3214.55	请登录
PL04752-50mg	50mg	¥4821.82	请登录
PL04752-100mg	100mg	¥7418.18	请登录
PL04752-200mg	200mg	询价	询价
PL04752-500mg	500mg	询价	询价
PL04752-10mM*1mLinDMSO	10mM*1mLinDMSO	¥1224.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Alofanib
中文别名	RPT835
英文名称	Alofanib
英文别名	RPT835;Alofanib;3-(N-(4-methyl-2-nitro-5-(pyridin-3-yl)phenyl)sulfamoyl)benzoic acid;LQX7RFK8MZ;Alofanib [INN];Alofanib(RPT835);Benzoic acid, 3-(((4-methyl-2-nitro-5-(3-pyridinyl)phenyl)amino)sulfonyl)-;SB19665;AK668992;ES000835
Cas No.	1612888-66-0
分子式	C₁₉H₁₅N₃O₆S
分子量	413.40
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Alofanib (RPT835)是高效和选择性的成纤维细胞生长因子受体2 (FGFR2) 的变构抑制剂。抗癌活性。抗血管生成活性。

生物活性

Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity.

性状

Solid

IC50 & Target[1][2]

FGFR2

体外研究(In Vitro)

Alofanib inhibits phosphorylation of FRS2α with IC50s of 7 and 9 nM in hFOB and SUM 52PE cells expressing different FGFR2 isoforms. Alofanib (0.2-0.8 μM, 6 hours) inhibits FGF-mediated proliferation in a panel of four cell lines representing several tumour types (triple-negative breast cancer, melanoma, and ovarian cancer) with GI50s of 16-370 nM. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

In a FGFR-driven human tumour xenograft model, oral administration of alofanib (30 mg/kg, gavage, daily, 40 days, N=10) is well tolerated and results in potent antitumour activity. Treatment with alofanib (10 mg/kg/d, 0, 3 and 6 d, intraperitoneally) ablates experimental FGF-induced angiogenesis in vivo. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Tsimafeyeu I, et al. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur J Cancer. 2016 Jul;61:20-8.
[2]. Khochenkov DA, et al. Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2. Bull Exp Biol Med. 2015 Nov;160(1):84-7.

溶解度数据	In Vitro: DMSO : ≥ 30.1 mg/mL (72.81 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation